Significance of liver resection for intermediate stage hepatocellular carcinoma according to subclassification

BMC Cancer. 2021 Jun 5;21(1):668. doi: 10.1186/s12885-021-08421-3.

Abstract

Background: Patients diagnosed with Barcelona Clinic Liver Cancer (BCLC) intermediate stage hepatocellular carcinoma (HCC) encompass a broad clinical population. Kinki criteria subclassifications have been proposed to better predict prognoses and determine appropriate treatment strategies for these patients. This study validated the prognostic significance within the Kinki criteria substages and analyzed the role of liver resection in patients with intermediate stage HCC.

Methods: Patients with intermediate stage HCC (n = 378) were retrospectively subclassified according to the Kinki criteria (B1, n = 123; B2, n = 225; and B3, n = 30). We analyzed the overall survival (OS) and treatment methods.

Results: The OS was significantly different between adjacent substages. Patients in substage B1 who underwent liver resection had a significantly better prognosis than those who did not, even after propensity score matching (PSM). Patients in substage B2 who underwent liver resection had a significantly better prognosis than those who did not; however, there was no difference after PSM. There was no difference in prognosis based on treatments among patients in substage B3.

Conclusions: The Kinki criteria clearly stratify patients with intermediate stage HCC by prognosis. For substage B1 HCC patients, liver resection provides a better prognosis than other treatment modalities. In patients with substage B2 and B3, an alternative approach is required.

Keywords: BCLC staging system; Hepatocellular carcinoma; Intermediate stage; Kinki criteria; Liver resection.

Publication types

  • Comparative Study
  • Validation Study

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / mortality
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / therapy*
  • Chemoembolization, Therapeutic / methods
  • Chemoembolization, Therapeutic / statistics & numerical data*
  • Cisplatin / administration & dosage
  • Female
  • Follow-Up Studies
  • Hepatectomy / statistics & numerical data*
  • Humans
  • Iodized Oil / administration & dosage
  • Kaplan-Meier Estimate
  • Liver / blood supply
  • Liver / drug effects
  • Liver / pathology
  • Liver / surgery
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / mortality
  • Liver Neoplasms / pathology
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Risk Assessment / methods
  • Sorafenib / administration & dosage
  • Treatment Outcome

Substances

  • Iodized Oil
  • Sorafenib
  • Cisplatin